Amgen, Aranesp
Aranesp: Death of a blockbuster
Apr/17/2007 06:20 Filed in: Pharma
Business
Amgen
Inc.'s drug
Aranesp didn't reduce the need for blood
transfusions in anemic cancer patients and was
linked to a nearly 45% increase in deaths
compared with patients taking a placebo. That's
really bad news for Amgen the maker of Aranesp
but there are a number of issues that go a lot
deeper here. When did Amgen know and why didn't
this data show up in the initial, and ongoing,
clinical trials? Lot's of questions that need to
be answered and someone needs to be held
accountable. Read
More...
|